✦ LIBER ✦

Use of xenogenized (modified) tumor cells for treatment in experimental tumor and in human neoplasia

✍ Scribed by S. Ben-Efraim; B. Bizzini; E.H. Relyveld

Book ID: 117575178
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 712 KB
Volume: 54
Category: Article
ISSN: 0753-3322
DOI: 10.1016/s0753-3322(00)80070-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

408 Enrichment of tumor cells for cell k

408 Enrichment of tumor cells for cell kinetic analysis in human tumor biopsies using cytokeratin gating

✍ I. Hofland; K. Haustermans; A.C. Begg 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Distribution of 4-hydroxy-2-nonenal-modi

Distribution of 4-hydroxy-2-nonenal-modified protein in experimental burn and human skin tumor

✍ Nakakuki, Yukari; Nishigori, Chikako; Toyokuni, Shinva; Uchida, Koji; Hiai, Hiro 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Use of monochlorobimane for glutathione

Use of monochlorobimane for glutathione measurements in hamster and human tumor cell lines

✍ J.A. Cook; H.I. Pass; A. Russo; S. Iype; J.B. Mitchell 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 456 KB

Targeting tumor vasculature endothelial

Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model

✍ Hu, Z. 📂 Article 📅 1999 🏛 National Academy of Sciences 🌐 English ⚖ 307 KB

Use of tumor-specific promoter for exper

Use of tumor-specific promoter for experimental gene therapy in small cell lung carcinoma

✍ Inase, N; Yoshizawa, Y 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 118 KB

Use of Xanthinol Nicotinate as a co-trea

Use of Xanthinol Nicotinate as a co-treatment for radio- and chemo-therapy in experimental tumors

✍ Jérome Segers; Nathalie Crokart; Pierre Danhier; Vincent Grégoire; Bénédicte F. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 210 KB

## Abstract The tumor micro‐environment plays a key role in the tumor resistance to cytotoxic treatments. It has been demonstrated that it is possible to modulate the tumor microenvironment to potentiate anti‐cancer therapy. Here, we made the hypothesis that the vasoactive agent xanthinol nicotinat